TARS Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. develops and manufactures drug treatments for Blepharitis. The company focuses on treatment of Blepharitis, which is a common ocular condition, characterized by inflammation of the eyelid, which can impact the anterior or posterior lid or both. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

$25.00  -2.70 (-9.75%)
As of 11/26/2021 13:00:00 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/15/2020
Outstanding shares:  20,676,992
Average volume:  25,366
Market cap:   $572,752,678
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    87650L103
ISIN:        US87650L1035
Sedol:      BMH5RL1
Valuation   (See tab for details)
PE ratio:   553.46
PB ratio:   2.88
PS ratio:   10.10
Return on equity:   -5.83%
Net income %:   -18.42%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy